References
- Bawezet O., et al. Europ. J. Clin. Pharmacol. 1983; 24: 145
- Helwig H. Arzneimittel, 6. Auflage, S. 87. Wissenschaftliche Verlagsgesellschaft mbH. Stuttgart 1988
- Lutz D., et al. Arz. Forschung 1985; 35: 1840–42
- Blume H., et al. Pharma Ztg. 1986; 131: 2534–2539
- Molz K. H., et al. Therapiewoche 1987; 37: 2953–2959
- General Provisions; procedures for determining the bioavailability of drug products; bioequivalence requirements. 1984; 117–135, Code of Federal Regulations. Nr. 21
- Koch-Weser J. Bioavailability of drugs. N Engl. J. Med. 1974; 291: 233–237; 503–506
- Koch-Weser J. Serum drug concentrations as therapeutic guides. N Engl. J. Med. 1972; 287: 227–231
- Seth P., U.S. Patent 4 795 643
- Meier J., et al. Europ. J. Clin. Pharmacol. 1974; 7: 429–432
- Dighe S. V., Adams W. P. Pharmacokinetics, P. G. Welling, F. L.S. Tse. Marcel Dekker Inc. 1988, Chapter 8
- Pharmacokinetics, M. Gibaldi, D. Perrier. Mercel Dekker Inc. 1975